Biogazelle Appoints Kris Vanhercke as Chief Operating Officer
News Sep 24, 2012
Biogazelle has announced the appointment of Kris Vanhercke as its new Chief Operating Officer.
Jo Vandesompele and Jan Hellemans, founders and CEO of Biogazelle, stated that this appointment marks a new phase for the company as it has set up a road map for growth. It strengthens its business development and marketing expertise.
Kris brings to Biogazelle an impressive track record from a 20-year career as a leading international executive within the medical device, diagnostics and life sciences industries.
Most recently, Kris was the Sales Director for Roche Diagnostics Belgium, where he was co-responsible for the company’s growth plan in the frame of delivering solutions in the vision of personalized healthcare (diagnostics and pharma).
Before that, he was the business unit manager for novel technologies in the life sciences, molecular diagnostics and tissue diagnostics arena.
He gained international experience when working in international launch teams in Switzerland and Germany and he has 15 years of experience in launching products and services in the clinical biology market.
He gained also experience as COO in the Gulf region (Middle East).
Kris started his career with a scientific-sales position at Boehringer Mannheim and gradually learned how to turn scientific ideas in to solid marketing concepts, developing business out of high-technology products in specific niche markets.
“Therefore, Kris is a great asset for Biogazelle in realizing its ambitious growth plans by exploiting his insights gained in a multi-national environment. Kris will help us to offer our products and services on a global level.” stated one of the founders Jo Vandesompele.
Commenting on his new role, Kris said: “Considering the dynamism of the team, the yes-we-can-attitude, together with the high-level scientific products and services offered today and in the pipeline, I believe that this company has the potential to grow as THE qPCR company. Moreover, Biogazelle has the potential to grow from a course and software provider to a service provider, offering complete solutions in gene expression, and microRNA and long non-coding RNA profiling.”
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Who Owns the Ocean? One Company Has Registered Half of All Marine Gene PatentsNews
A single corporation has registered nearly half of all existing patents associated with genes from marine organisms, according to a new study. Researchers from the University of British Columbia and the Stockholm Resilience Centre examined the patents associated with marine species and found that BASF, the world’s largest chemical manufacturer, has registered 47 per cent of the 12,998 genetic sequences from 862 marine species.